Federal Circuit: PTAB Erred On ‘Unexpected Results’ In GI Drug Patent Row
WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel vacated a U.S. Patent Trial and Appeal Board (PTAB) decision to uphold a drugmaker’s patent on a molecule for use...To view the full article, register now.
Already a subscriber? Click here to view full article